【本草纲目是哪个国家的品牌？】

外推网助力本草纲目品牌出海！将品牌入驻外推网，定制本草纲目品牌推广信息，可以显著提高本草纲目产品曝光，简直是跨境电商爆单神器！目前仅需1000元/年哦~

李时珍医药集团有限公司，本草纲目，知名医药品牌，湖北省著名商标，华中地区中药现代化生产基地，被称之为“华中药谷”，集药品科研/种植/生产/教学/科普/旅游观光/医疗保健于一体医药集团

李时珍医药集团组建于2002年，位于医圣故里——湖北蕲春本草纲目生物科技园区，是一家跨地区、现代化的大型台资中药生产企业。现有湖北李时珍药业股份有限公司、厦门美商医药有限公司等13家控股子公司，母公司为李时珍医药集团有限公司，资产总额超过10亿元。李

按“百年企业、百亿企业”的“双百”长远规划，集团分六期建设，其中一、二期项目已于 2003年、2012年建成投产，总投资3亿元，总建筑面积55000㎡，年生产规模30亿元，先后通过国家新版GMP认证。三期项目于2012年动工兴建，计划总投资2.5亿元，设计年生产能力40亿元，目前已建成中药超微粉碎大楼和酿酒制剂生产大楼，并投入生产；基药和露剂生产大楼总建筑面积25000㎡，设计年生产能力20亿元（其中基药年产值15亿元，保健饮品年产值5亿元），已从国家基本药物目录中遴选乌鸡白凤丸、六味地黄丸、杞菊地黄丸、补中益气丸、麻仁丸等28个中成药产品在这里集中生产，并于2017年1月通过国家GMP认证。

经过14年发展创新，集团基本形成产品多元化（中成药、保健酒、中药饮片、大健康系列产品等）、市场网络化、管理科学化、团队年轻化的医药产业发展新格局。

英文翻译：Li Shizhen Pharmaceutical Group Co., Ltd., compendium of Materia Medica, famous pharmaceutical brand, famous trademark of Hubei Province, modern production base of traditional Chinese medicine in Central China, known as "Huazhong pharmaceutical Valley", a pharmaceutical group integrating pharmaceutical research / planting / production / teaching / popular science / Tourism / health care, Li Shizhen Pharmaceutical Group was established in 2002, located in the hometown of medical sage, compendium of Qichun Materia Medica, Hubei Province Biotechnology Park is a large-scale, cross regional and modern Taiwan funded Chinese medicine production enterprise. At present, there are 13 holding subsidiaries including Hubei lishizhen Pharmaceutical Co., Ltd. and Xiamen Meishang Pharmaceutical Co., Ltd. and the parent company is lishizhen Pharmaceutical Group Co., Ltd. with total assets of more than 1 billion yuan. According to the long-term plan of "100 years and 10 billion enterprises", the group is divided into six phases. The first and second phases of the project have been completed and put into operation in 2003 and 2012, with a total investment of 300 million yuan, a total construction area of 55000 ㎡, and an annual production scale of 3 billion yuan. The project has passed the national GMP certification. The third phase of the project was started in 2012, with a total planned investment of 250 million yuan and a designed annual production capacity of 4 billion yuan. At present, the ultramicro pulverizing building of traditional Chinese medicine and the production building of brewing preparation have been built and put into production. The total construction area of the production building of basic medicine and dew agent is 25000 square meters, and the designed annual production capacity is 2 billion yuan (including the annual output value of 1.5 billion yuan for basic medicine and 500 million yuan for health drinks), which has been transferred from the national base 28 Chinese patent medicine products, such as Wuji Baifeng pill, Liuwei Dihuang pill, Qiju Dihuang pill, Buzhong Yiqi pill and Maren pill, are selected in this drug catalog for centralized production and passed the national GMP certification in January 2017. After 14 years of development and innovation, the group has basically formed a new pattern of pharmaceutical industry development with diversified products (Chinese patent medicine, health wine, Chinese herbal pieces, large health series products, etc.), market networking, scientific management and younger team.

本文链接： https://www.waitui.com/brand/3a2ce8133.html 联系电话：请联系客服添加 联系邮箱：请联系客服添加